NEWLIMIT

Summary

NewLimit is a biotechnology company working to extend human healthspan by developing epigenetic reprogramming therapies.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 32 M

Avg. Deal Size£ 32 M

Market Context

Senior Management